Humacyte FY2026 EPS Estimate Increased by HC Wainwright

Humacyte, Inc. (NASDAQ:HUMA) – Analysts at HC Wainwright boosted their FY2026 EPS estimates for Humacyte in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.37) per share for the year, up from their prior estimate of ($0.50). The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share. HC Wainwright also issued estimates for Humacyte’s FY2027 earnings at ($0.27) EPS, FY2028 earnings at ($0.06) EPS, FY2029 earnings at $0.10 EPS and FY2030 earnings at $0.38 EPS.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Friday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $1.35 million. Humacyte had a negative return on equity of 990.48% and a negative net margin of 1,998.87%.

Other equities analysts have also recently issued reports about the company. Benchmark reduced their target price on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. Wall Street Zen lowered Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Friday, March 27th. BTIG Research reduced their price objective on shares of Humacyte from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, March 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Humacyte currently has a consensus rating of “Moderate Buy” and an average price target of $7.71.

Humacyte Trading Up 8.5%

NASDAQ HUMA opened at $0.64 on Thursday. The stock has a market cap of $120.30 million, a P/E ratio of -3.21 and a beta of 2.11. Humacyte has a fifty-two week low of $0.55 and a fifty-two week high of $2.93. The stock has a 50 day simple moving average of $1.01 and a two-hundred day simple moving average of $1.26. The company has a debt-to-equity ratio of 20.08, a quick ratio of 0.90 and a current ratio of 3.69.

Hedge Funds Weigh In On Humacyte

Several large investors have recently made changes to their positions in the business. R Squared Ltd bought a new stake in shares of Humacyte in the 4th quarter worth approximately $25,000. Atom Investors LP bought a new position in Humacyte during the 4th quarter valued at approximately $25,000. Truist Financial Corp bought a new position in Humacyte during the 3rd quarter valued at approximately $28,000. Prudential Financial Inc. purchased a new position in Humacyte during the second quarter valued at $28,000. Finally, Financial Advisors Network Inc. purchased a new position in Humacyte during the second quarter valued at $28,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.